Claims for Patent: 8,894,988

Summary for Patent: 8,894,988

Title:	Tamper resistant dosage forms
Abstract:	The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.
Inventor(s):	McKenna; William H. (Yonkers, NY), Mannion; Richard O. (Furlong, PA), O'Donnell; Edward P. (Basking Ridge, NJ), Huang; Haiyong H. (Princeton, NJ)
Assignee:	Purdue Pharma L.P. (Stamford, CT) Purdue Pharmaceuticals L.P. (Wilson, NC)
Application Number:	13/900,963
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,894,988
Patent Claims:	1. A cured shaped tablet comprising an extended release matrix comprising a composition, wherein said tablet comprises: (1) at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of 4,000,000, and (2) oxycodone or a pharmaceutically acceptable salt, and wherein said tablet is prepared by a process comprising the steps of: (a) combining at least (1) and (2) to form a blend; (b) shaping said blend to form a shaped tablet; and (c) curing said shaped tablet by subjecting the shaped tablet to a temperature from about 60 to about 90.degree. C. for a time of from about 15 minutes to about 10 hours, wherein said cured shaped tablet comprises: (i) 5, 7.5, 10, 15, 20, or 30 mg of said oxycodone or pharmaceutically acceptable salt and at least 79% by weight, based upon the total weight of said composition, of said at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of 4,000,000; (ii) 40 mg of said oxycodone or pharmaceutically acceptable salt and at least 72% by weight, based upon the total weight of said composition, of said at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of 4,000,000; (iii) 60 mg of said oxycodone or pharmaceutically acceptable salt and at least 57% by weight, based upon the total weight of said composition, of said at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of 4,000,000; or (iv) 80 mg of said oxycodone or pharmaceutically acceptable salt and at least 54% by weight, based upon the total weight of said composition, of said at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of 4,000,000. 2. A cured shaped tablet as defined in claim 1, wherein said oxycodone or pharmaceutically acceptable salt is oxycodone hydrochloride. 3. A cured shaped tablet as defined in claim 1, wherein said time in said curing step is 30 minutes to 90 minutes. 4. A cured shaped tablet as defined in claim 1, wherein said temperature in said curing step is from 62 to 90.degree. C. 5. A cured shaped tablet as defined in claim 1, wherein said shaped tablet is coated before or after said curing step. 6. A cured shaped tablet comprising an extended release matrix comprising a composition, wherein said tablet comprises: (1) at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of 4,000,000 and (2) an opioid analgesic or a pharmaceutically acceptable salt; wherein said tablet is prepared by a process comprising the steps of: (a) combining at least (1) and (2) to form a blend; (b) shaping said blend to form a shaped tablet; and (c) curing said shaped tablet by subjecting the shaped tablet to a temperature from about 60 to about 90.degree. C. for a time of from about 15 minutes to about 10 hours, wherein said polyethylene oxide having, based on rheological measurements, an approximate molecular weight of 4,000,000, in said blend is in an amount of at least 79% by weight, based upon the total weight of said composition. 7. A cured shaped tablet as defined in claim 6, wherein, said temperature in said curing step is from 62 to 90.degree. C. 8. A cured shaped tablet as defined in claim 6, wherein said shaped tablet is coated before or after said curing step. 9. A cured shaped tablet as defined in claim 6, wherein said opioid analgesic or pharmaceutically acceptable salt comprises hydrocodone or a pharmaceutically acceptable salt thereof. 10. A cured shaped tablet as defined in claim 6, wherein said opioid analgesic or pharmaceutically acceptable salt comprises hydromorphone or a pharmaceutically acceptable salt thereof. 11. A cured shaped tablet as defined in claim 10, wherein said hydromorphone or a pharmaceutically acceptable salt thereof comprises hydromorphone hydrochloride. 12. A cured shaped tablet as defined in claim 6, wherein said opioid analgesic or pharmaceutically acceptable salt comprises oxymorphone or a pharmaceutically acceptable salt thereof. 13. A cured shaped tablet as defined in claim 12, wherein said oxymorphone or a pharmaceutically acceptable salt thereof comprises oxymorphone hydrochloride. 14. A cured shaped tablet as defined in claim 6, wherein said opioid analgesic or pharmaceutically acceptable salt comprises morphine or a pharmaceutically acceptable salt thereof. 15. A cured shaped tablet as defined in claim 1, wherein said cured shaped tablet comprises 5, 7.5, 10, 15, 20, or 30 mg of said oxycodone or pharmaceutically acceptable salt and at least 79% by weight, based upon the total weight of said composition, of said at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of 4,000,000. 16. A cured shaped tablet as defined in claim 1, wherein said cured shaped tablet comprises 40 mg of said oxycodone or pharmaceutically acceptable salt and at least 72% by weight, based upon the total weight of said composition, of said at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of 4,000,000. 17. A cured shaped tablet as defined in claim 1, wherein said cured shaped tablet comprises 60 mg of said oxycodone or pharmaceutically acceptable salt and at least 57% by weight, based upon the total weight of said composition, of said at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of 4,000,000. 18. A cured shaped tablet as defined in claim 1, wherein said cured shaped tablet comprises 80 mg of said oxycodone or pharmaceutically acceptable salt and at least 54% by weight, based upon the total weight of said composition, of said at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of 4,000,000. 19. A cured shaped tablet as defined in claim 1, wherein said tablet is prepared by a process comprising the steps of: (a) combining at least (1) and (2) to form a blend; (b) shaping said blend by compression to form a shaped tablet; and (c) curing said shaped tablet by subjecting the shaped tablet to a temperature from about 60 to about 90.degree. C. for a time of from about 15 minutes to about 10 hours. 20. A cured shaped tablet as defined in claim 19, wherein said cured shaped tablet comprises 5, 7.5, 10, 15, 20, or 30 mg of said oxycodone or pharmaceutically acceptable salt and at least 79% by weight, based upon the total weight of said composition, of said at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of 4,000,000. 21. A cured shaped tablet as defined in claim 19, wherein said cured shaped tablet comprises 40 mg of said oxycodone or pharmaceutically acceptable salt and at least 72% by weight, based upon the total weight of said composition, of said at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of 4,000,000. 22. A cured shaped tablet as defined in claim 19, wherein said cured shaped tablet comprises 60 mg of said oxycodone or pharmaceutically acceptable salt and at least 57% by weight, based upon the total weight of said composition, of said at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of 4,000,000. 23. A cured shaped tablet as defined in claim 19, wherein said cured shaped tablet comprises 80 mg of said oxycodone or pharmaceutically acceptable salt and at least 54% by weight, based upon the total weight of said composition, of said at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of 4,000,000. 24. A cured shaped tablet as defined in claim 1, wherein said curing comprises convection curing in a convection curing device. 25. A cured shaped tablet as defined in claim 6, wherein said curing comprises convection curing in a convection curing device. 26. A cured shaped tablet as defined in claim 19, wherein said curing comprises curing in a convection curing device. 27. A cured shaped tablet as defined in claim 1, wherein said cured shaped tablet has a density that is at least about 1% lower than the density of said shaped tablet prior to curing. 28. A cured shaped tablet as defined in claim 6, wherein said cured shaped tablet has a density that is at least about 1% lower than the density of said shaped tablet prior to curing. 29. A cured shaped tablet as defined in claim 19, wherein said cured shaped tablet has a density that is at least about 1% lower than the density of said shaped tablet prior to curing. 30. A cured shaped tablet as defined in claim 19, wherein said cured shaped tablet has a density that is at least about 2% lower than the density of said shaped tablet prior to curing.